News

Back in early June, Pulmonary Hypertension News profiled PH advocates Team Phenomenal Hope and their compelling bicycle trek through twelve states, 3,000 miles, and 170,000 vertical feet of elevation, in order to raise money and awareness for the disease. The race, which began on June, 14th in Oceanside, California, concluded…

Cambridge University professor Nicholas Morrell, a leading researcher specializing in the study of heart disease, was recently awarded a £200,000 grant ($342,920) to investigate the causes of inherited pulmonary arterial hypertension. The award was granted by the British Heart Foundation (BHF), an organization engaged in helping the 3,200 people in…

Bellerophon Therapeutics, a biotherapeutics company working on a therapeutic treatment for pulmonary arterial hypertension, announced yesterday that Jonathan Peacock has been appointed chairman and chief executive officer. A graduate in Economics from the University of St. Andrews in Scotland, Peacock, who will replace Daniel Tassé in the role of chairman and…

Bellerophon Therapeutics, who recently completed enrollment for a Phase 2 clinical trial evaluating INOpulse in patients with pulmonary hypertension, has fully enrolled another Phase 2 clinical trial, this time evaluating INOpulse in 159 pulmonary hypertension…

Irving, Texas based Reata Pharmaceuticals, Inc. has enrolled the first patient in a Phase 2 dose ranging study examining the safety, tolerability, and efficacy of bardoxolone methyl in patients with pulmonary arterial hypertension (PAH). PAH is a life-threatening disease involving endothelial dysfunction, vasoconstriction in small pulmonary arteries, aberrant…

Pulmonary arterial hypertension (PAH) affects females more often than males. Since a major difference between females and males is their respective levels of estrogen production, estrogen is thought to play a role in PAH pathology. A group of researchers from the University of Glasgow and the Novartis…

Researchers in a major study based at Brigham and Women’s Hospital (BWH) in Boston, Massachusetts, have linked development of the deadly vascular disease pulmonary hypertension (PH) to a related family of molecules, and show that the disorder’s progression involves disparate molecular pathways that span multiple cell types. MicroRNAs…

Genomics development and commercialization specialist firm Synthetic Genomics Inc. (SGI) of La Jolla, CA, and Silver Spring, Maryland-based Lung Biotechnology Inc., a subsidiary of United Therapeutics Corporation, have entered into a multi-year research and development agreement to develop humanized pig organs using synthetic genomic advances. The…

SteadyMed Therapeutics, a pharmaceutical company focused on developing drugs to treat underserved medical needs in orphan and high value disease states, recently announced a development and manufacturing agreement with Bespak Europe, a Consort Medical company and supplier of drug delivery devices for injectable and inhaled products. The two companies will join efforts to produce…

Yoga for PH is a novel exercise program developed by Henry Ford Hospital to improve balance, strength, reduce stress and calm the nervous system of patients with pulmonary hypertension. The first-of-its-kind 40-minute program includes three levels of yoga exercises and a nutrition and lifestyle guide and is already available…

The nutritional supplement N-acetylcysteine (NAC) may have immunomodulatory and cardioprotective properties, which can potentially benefit pulmonary hypertension patients, according to the recent study “N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats,” conducted by Dr. Marie-Camille Chaumais, at the University of Paris-Sud, College of Pharmacy, France. As the pathophysiology of pulmonary arterial hypertension…

Biothech company Bellerophon Therapeutics met the enrollment goal for its Phase 2 clinical trial evaluating INOpulse in patients with pulmonary arterial hypertension. Eighty patients, with age limits of 16-80 years, were enrolled at 52 sites across the United States and Canada. INOpulse is pulsed, inhaled nitric oxide.